182 related articles for article (PubMed ID: 15629636)
1. Modeling prostate cancer: in regards to Nahum et al. (Int J Radiat Oncol Biol Phys 2003;57:391-401).
Wang JZ; Mayr NA; Li XA; Stewart RD
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):309-10; author reply 310-1. PubMed ID: 15629636
[No Abstract] [Full Text] [Related]
2. In regard to Nahum et al. (Int J Radiat Oncol Biol Phys 2003;57:391-401): Incorporating clinical measurements of hypoxia into tumor control modeling of prostate cancer: implications for the alpha/beta ratio.
Orton CG
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1637; author reply 1637-9. PubMed ID: 15050348
[No Abstract] [Full Text] [Related]
3. Response to "Stereotactic ablative radiotherapy in the framework of classical radiobiology: response to Drs. Brown, Diehn, and Loo." (Int J Radiat Oncol Biol Phys 2011;79:1599-1600) and "Influence of tumor hypoxia on stereotactic ablative radiotherapy (SABR): response to Drs. Mayer and Timmerman." (Int J Radiation Oncol Biol Phys 2011;78:1600).
Song CW; Levitt SH; Park H
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1193; author reply 1193-4. PubMed ID: 22036162
[No Abstract] [Full Text] [Related]
4. Toward a unified survival curve: in regard to Park et al. (IntJ Radiat Oncol Biol Phys 2008;70:847-852) and Krueger et al. (Int J Radiat Oncol Biol Phys 2007;69:1262-1271).
Kavanagh BD; Newman F
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):958-9. PubMed ID: 18514788
[No Abstract] [Full Text] [Related]
5. MRI for cervical cancer not only correlates with tumor hypoxia, but also predicts ultimate outcome: in regard to Lim et al. (Int J Radiat Oncol Biol Phys 2008;70:126-133).
Wang JZ; Mayr NA; Zhang D; Yuh WT
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1602-3; author reply 1603. PubMed ID: 18640508
[No Abstract] [Full Text] [Related]
6. In regards to Thames et al.: increasing external beam dose for T1-T2 prostate cancer: effect on risk groups. (Int J Radiat Oncol Biol Phys 2006;65:975-981).
Pickles T; Williams SG
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):318-9; author reply 319. PubMed ID: 17189080
[No Abstract] [Full Text] [Related]
7. Radiobiological parameters suitable for modeling individual outcomes cannot be obtained by analyzing heterogeneous population data with homogeneous tumor control model: in regard to D'Souza et al. (Int J Radiat Oncol Biol Phys 2004;58:1540-1548).
Carlone M; Wilkins D; Raaphorst GP
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):298-9. PubMed ID: 15850946
[No Abstract] [Full Text] [Related]
8. In regard to Fiorino et al.: Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer (Int J Radiat Oncol Biol Phys 2003;57:953-962).
Bauman G; Rodrigues G
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):912-4; author reply 914-5. PubMed ID: 15183497
[No Abstract] [Full Text] [Related]
9. In regard to "Dose escalation in the radiation therapy of prostate cancer" (Int J Radiat Oncol Biol Phys 2011;80:1289-1291).
Bowes D; Crook J
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1317-8. PubMed ID: 22385710
[No Abstract] [Full Text] [Related]
10. A new method for synthesizing radiation dose-response data from multiple trials applied to prostate cancer: in regard to Diez P, et al. (Int J Radiat Oncol Biol Phys 2010;77:1066-1071).
Williams SG
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):639; author reply 639-40. PubMed ID: 21549251
[No Abstract] [Full Text] [Related]
11. Fractionation and late rectal toxicity: no reliable estimates of alpha/beta value for rectum can be derived from studies where different volumes of rectum are irradiated at different dose levels: in regard to Brenner (Int J Radiat Oncol Biol Phys 2004;60:1013-1015.).
Fiorino C; Sanguineti G; Valdagni R
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):289-90; author reply 290-1. PubMed ID: 15850935
[No Abstract] [Full Text] [Related]
12. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer: in regard to Arcangeli C, et al. (Int J Radiat Oncol Biol Phys 2010;78:11-18).
Vogelius IR; Bentzen SM
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):316; author reply 316-7. PubMed ID: 21481731
[No Abstract] [Full Text] [Related]
13. In regard to Arvold et al. (Int J Radiat Oncol Biol Phys 2005;62:207-212).
Moeller BJ; Dewhirst MW
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):970-1; author reply 971. PubMed ID: 16199328
[No Abstract] [Full Text] [Related]
14. In regard to Trofimov et al.: Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison (Int J Radiat Oncol Biol Phys 2007;69:444-453).
Albertini F; Lomax AJ; Hug EB
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1333-4; author reply 1334-5. PubMed ID: 17967323
[No Abstract] [Full Text] [Related]
15. In regards to Wallner et al: (125)I versus (103)PD for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial (Int J Radiat Oncol Biol Phys 2003;57:1297-1303).
Lee WR
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):319; author reply 319-20. PubMed ID: 15093929
[No Abstract] [Full Text] [Related]
16. Volumetric modulated arc therapy for delivery of prostate radiotherapy: in regard to Palma et al. (Int J Radiat Oncol Biol Phys 2008;70:996-1001).
Ost P; Fonteyne V; De Neve W; De Gersem W; De Wagter C; Vandecasteele K; Duprez F; De Meerleer G
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1286; author reply 1287. PubMed ID: 19251105
[No Abstract] [Full Text] [Related]
17. BED calculations for fractions of very high dose: in regard to Park et al. (Int J Radiat Oncol Biol Phys 2007;69:S623-S624).
Astrahan M
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):963; author reply 963-4. PubMed ID: 18514798
[No Abstract] [Full Text] [Related]
18. Toward a unified survival curve: in regard to Kavanagh and Newman (Int J Radiat Oncol Biol Phys 2008;71:958-959) and Park et al. (IntJ Radiat Oncol Biol Phys 2008;70:847-852).
McKenna F; Ahmad S
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):640; author reply 640-1. PubMed ID: 19147035
[No Abstract] [Full Text] [Related]
19. The need and prospect of individualized external beam radiotherapy dose escalation beyond 80 gy to treat prostate cancer: in regard to Eade et al. (Int J. Radiat. Oncol. Biol. Phys. 2007;68:682-689).
Cheung MR
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):645; author reply 645-6. PubMed ID: 18207039
[No Abstract] [Full Text] [Related]
20. Randomized trial of high- and low-source strength (125)I prostate seed implants: In regard to Narayana et al. (Int J Radiat Oncol Biol Phys 2005;61:44-51).
Moerland MA; Battermann JJ
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):941-2. PubMed ID: 15936582
[No Abstract] [Full Text] [Related]
[Next] [New Search]
